US 11,883,375 B2
Mirdametinib treatment
Uchenna H Iloeje, Stamford, CT (US); Abraham J Langseth, Stamford, CT (US); and Todd Shearer, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics Inc., Stamford, CT (US)
Filed on Jun. 14, 2023, as Appl. No. 18/334,518.
Application 18/334,518 is a continuation of application No. 18/185,148, filed on Mar. 16, 2023.
Claims priority of provisional application 63/321,036, filed on Mar. 17, 2022.
Claims priority of provisional application 63/321,046, filed on Mar. 17, 2022.
Prior Publication US 2023/0321014 A1, Oct. 12, 2023
Int. Cl. A61K 31/166 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 31/216 (2006.01); A61P 25/00 (2006.01)
CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61K 31/216 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 35/00 (2018.01)] 30 Claims
 
1. A method of treating a human patient 2 years or older who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) comprising orally administering an effective amount of mirdametinib to the patient, wherein
(I) an amount of mirdametinib is administered on the first day of treatment to provide an AUC0-tau less than 300 ng·h/mL; and
(II) (a) for a patient having a body surface area no more than 0.69 m2, the patient is initially administered 1 mg mirdametinib,
(b) for a patient having a body surface area of 0.7 to 1.04 m2, the patient is initially administered 2 mg mirdametinib, or
(c) for a patient having a body surface area of 1.05 to 1.49 m2, the patient is initially administered 3 mg mirdametinib.